TCL1B Human

T-cell Leukemia/Lymphoma 1B (TCL1B) is a protein that plays a significant role in the development and progression of certain types of leukemia and lymphoma. This protein is part of the TCL1 family, which includes TCL1A, TCL1B, and MTCP1. These proteins are known for their involvement in the regulation of T-cell proliferation and survival. The recombinant form of TCL1B, referred to as Human Recombinant TCL1B, is produced through recombinant DNA technology, allowing for its use in various research and therapeutic applications.

TCL1B is a small protein composed of approximately 114 amino acids. It shares a high degree of homology with other members of the TCL1 family, particularly TCL1A. The protein is characterized by its ability to form homodimers and heterodimers, which are essential for its function. TCL1B interacts with several key signaling molecules, including AKT (protein kinase B), which is crucial for cell survival and proliferation.

The primary function of TCL1B is to enhance the activation of AKT. This activation leads to the promotion of cell survival and proliferation, particularly in T-cells. By interacting with AKT, TCL1B helps to prevent apoptosis (programmed cell death) and supports the growth and division of T-cells. This function is particularly relevant in the context of T-cell leukemia and lymphoma, where uncontrolled cell proliferation is a hallmark of the disease.

TCL1B has been implicated in the pathogenesis of several types of T-cell malignancies, including T-cell prolymphocytic leukemia (T-PLL) and adult T-cell leukemia/lymphoma (ATL). Overexpression of TCL1B has been observed in these diseases, suggesting that it plays a role in their development and progression. The protein’s ability to enhance AKT activation is believed to contribute to the uncontrolled proliferation of malignant T-cells.

In addition to its role in T-cell malignancies, TCL1B has also been studied in the context of other cancers, such as B-cell lymphomas and solid tumors. Its involvement in these diseases highlights the broader significance of TCL1B in cancer biology.

The recombinant form of TCL1B, Human Recombinant TCL1B, is produced using recombinant DNA technology. This involves the insertion of the TCL1B gene into a suitable expression system, such as bacteria or mammalian cells, to produce the protein in large quantities. The availability of recombinant TCL1B has facilitated numerous research studies aimed at understanding its function and role in disease.

In the research setting, Human Recombinant TCL1B is used to study the molecular mechanisms underlying T-cell leukemia and lymphoma. It is also employed in drug discovery efforts to identify potential therapeutic targets for these diseases. By elucidating the pathways regulated by TCL1B, researchers hope to develop novel treatments that can inhibit its function and thereby control the proliferation of malignant cells.